Prescient Therapeutics (ASX:PTX) has dosed the first patient in its phase 2a clinical study of cancer treatment candidate PTX-100, a compound with the ability to block an important cancer growth enzyme, according to a Tuesday filing with the Australian bourse.

The study will evaluate two dosage levels of PTX-100 in about 40 patients with relapsed/refractory cutaneous T-cell lymphoma on an open-label basis. Its primary endpoint is efficacy, with safety as part of the secondary endpoints, the filing said.

Company shares rose 4% in recent trade.